Cargando…
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer
Impressive clinical benefit is seen in clinic with PD‐1 inhibitors on portion of cancer patients. Yet, there remains an urgent need to develop effective synergizers to expand their clinical application. Tumor‐associated macrophage (TAM), a type of M2‐polarized macrophage, eliminates or suppresses T‐...
Autores principales: | Zhou, Qian, Liang, Jinxia, Yang, Tong, Liu, Jin, Li, Bo, Li, Yingchang, Fan, Zhenzhen, Wang, Weida, Chen, Wensheng, Yuan, Sujing, Xu, Meng, Xu, Qigui, Luan, Zhidong, Xia, Zhongjun, Zhou, Penghui, Huang, Yadong, Chen, Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749493/ https://www.ncbi.nlm.nih.gov/pubmed/34898004 http://dx.doi.org/10.15252/emmm.202114502 |
Ejemplares similares
-
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021) -
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023) -
Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming
por: Liang, Yuanzheng, et al.
Publicado: (2022) -
Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer
por: Zhou, Qian, et al.
Publicado: (2021) -
MTHFR act as a potential cancer biomarker in immune checkpoints blockades, heterogeneity, tumor microenvironment and immune infiltration
por: Peng, Jianheng, et al.
Publicado: (2023)